We only have this paper's title and publication details.
Read it at the sourceThis editorial comments on the status and future perspectives of molecular residual disease testing in genitourinary cancers, indicating its significance.
The author declares no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Fumihiko Urabe (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: